Capricor Therapeutics (NASDAQ CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. At the forefront of our innovation is Deramiocel (CAP-1002) our lead cell therapy in late-stage development for Duchenne muscular dystrophy. We are also harnessing our proprietary StealthX exosome platform to unlock new possibilities in targeted delivery and vaccinology. Every program reflects our commitment to pushing the boundaries of science and delivering life-changing treatments to patients and families who need them most. The Senior Director Head of Patient Services will lead the design implementation and ongoing management of Capricor's U.S. patient services organization in support of the anticipated launch of deramiocel Capricor's lead cell therapy for Duchenne muscular dystrophy. This leader will … Sign In to View